2-year follow-up of Nevo RES-elution I, a randomisedmulticentre comparison of the Nevo Sirolimus-eluting coronarystent system using RES technology with the Taxus LibertéPaclitaxel-eluting stent
EuroIntervention
; 07: 1-2, 2014.
Article
em En
| SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1062675
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
Aims:
The NEVO sirolimus eluting coronary stent is designed to improvelong-term PCI safety by combining sirolimus release from reservoirs withbioabsorbable polymer to reduce spatial and temporal polymer exposure.Absorption of drug and polymer within approximately three months limits theduration of vessel wall exposure to the polymer. Thereafter, only a biologically inertbare-metal platform remains. The NEVO stent was first evaluated in the multicenterrandomised NEVO RES-Elution I trial which demonstrated its superiority tothe TAXUS Liberté Paclitaxel - eluting stent.
Texto completo:
1
Base de dados:
SES-SP
/
SESSP-IDPCPROD
Assunto principal:
Stents
/
Constrição Patológica
/
Sirolimo
Idioma:
En
Ano de publicação:
2014